[go: up one dir, main page]

SI3399984T1 - Modulatorji 5'-nukleotidaze, ekto, in njihova uporaba - Google Patents

Modulatorji 5'-nukleotidaze, ekto, in njihova uporaba

Info

Publication number
SI3399984T1
SI3399984T1 SI201731439T SI201731439T SI3399984T1 SI 3399984 T1 SI3399984 T1 SI 3399984T1 SI 201731439 T SI201731439 T SI 201731439T SI 201731439 T SI201731439 T SI 201731439T SI 3399984 T1 SI3399984 T1 SI 3399984T1
Authority
SI
Slovenia
Prior art keywords
ekto
nucleotidase
modulators
nucleotidase modulators
Prior art date
Application number
SI201731439T
Other languages
English (en)
Inventor
Laurent Pierre Paul Debien
Juan Carlos Jaen
Jaroslaw Kalisiak
Kenneth V. LAWSON
Manmohan Reddy Leleti
Erick Allen Lindsey
Dillon Harding Miles
Eric Newcomb
Jay Patrick Powers
Brandon Reid Rosen
Ehesan Ui Sharif
Original Assignee
Arcus Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences, Inc. filed Critical Arcus Biosciences, Inc.
Publication of SI3399984T1 publication Critical patent/SI3399984T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
SI201731439T 2016-01-08 2017-01-06 Modulatorji 5'-nukleotidaze, ekto, in njihova uporaba SI3399984T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662276564P 2016-01-08 2016-01-08
US201662324077P 2016-04-18 2016-04-18
EP17736459.3A EP3399984B1 (en) 2016-01-08 2017-01-06 Modulators of 5'-nucleotidase, ecto and the use thereof
PCT/US2017/012587 WO2017120508A1 (en) 2016-01-08 2017-01-06 Modulators of 5'-nucleotidase, ecto and the use thereof

Publications (1)

Publication Number Publication Date
SI3399984T1 true SI3399984T1 (sl) 2024-01-31

Family

ID=59274491

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731439T SI3399984T1 (sl) 2016-01-08 2017-01-06 Modulatorji 5'-nukleotidaze, ekto, in njihova uporaba

Country Status (29)

Country Link
US (5) US10239912B2 (sl)
EP (2) EP4306525A3 (sl)
JP (4) JP6920344B2 (sl)
KR (1) KR102772803B1 (sl)
CN (3) CN119912510A (sl)
AU (2) AU2017206061B2 (sl)
BR (1) BR112018013827B1 (sl)
CA (2) CA3009196C (sl)
CL (1) CL2018001845A1 (sl)
DK (1) DK3399984T3 (sl)
EA (1) EA038565B1 (sl)
ES (1) ES2963759T3 (sl)
FI (1) FI3399984T3 (sl)
HR (1) HRP20231155T1 (sl)
HU (1) HUE063388T2 (sl)
IL (1) IL260260B2 (sl)
LT (1) LT3399984T (sl)
MX (2) MX2018008350A (sl)
MY (1) MY204877A (sl)
PH (1) PH12018501361A1 (sl)
PL (1) PL3399984T3 (sl)
PT (1) PT3399984T (sl)
SA (1) SA518391985B1 (sl)
SG (1) SG11201805506YA (sl)
SI (1) SI3399984T1 (sl)
TW (2) TW202227095A (sl)
UA (1) UA124529C2 (sl)
WO (1) WO2017120508A1 (sl)
ZA (2) ZA201804350B (sl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124529C2 (uk) 2016-01-08 2021-10-05 Аркус Байосайєнсіз, Інк. Модулятори екто-5-нуклеотидази та їх застосування
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CN110022881B (zh) * 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
MY200641A (en) 2016-12-08 2024-01-08 Hoffmann La Roche New isoxazolyl ether derivatives as gaba a alpha5 pam
NZ754171A (en) * 2016-12-22 2022-12-23 Calithera Biosciences Inc Ectonucleotidase inhibitors and methods of use thereof
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
JP7274469B2 (ja) 2017-10-06 2023-05-16 イナート・ファルマ・ソシエテ・アノニム Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019129059A1 (zh) * 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
CN112004541A (zh) * 2018-03-09 2020-11-27 艾库斯生物科学有限公司 肠道外给药的免疫增强药物
KR20210018255A (ko) * 2018-04-30 2021-02-17 오릭 파마슈티칼스, 인크. Cd73 억제제
US12331068B2 (en) 2018-05-31 2025-06-17 Peloton Therapeutics, Inc. Compositions and methods for inhibiting CD73
US11377503B2 (en) 2018-06-18 2022-07-05 Innate Pharma Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
US20210169911A1 (en) * 2018-08-17 2021-06-10 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors
WO2020047082A1 (en) 2018-08-28 2020-03-05 Eternity Bioscience Inc. Cd73 inhibitors and therapeutic uses thereof
CN110885352B (zh) * 2018-09-11 2023-02-24 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
EP3849992A4 (en) 2018-09-11 2022-06-29 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
EP3893891A4 (en) * 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
SG11202106963YA (en) 2019-01-11 2021-07-29 Omeros Corp Methods and compositions for treating cancer
WO2020151707A1 (zh) * 2019-01-22 2020-07-30 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
US12453738B2 (en) 2019-03-12 2025-10-28 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
WO2020205538A1 (en) * 2019-03-29 2020-10-08 Eternity Bioscience Inc. Cd73 inhibitors and therapeutic uses thereof
CA3135487A1 (en) * 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
JP2022527556A (ja) * 2019-04-05 2022-06-02 プレリュード・セラピューティクス・インコーポレイテッド プロテインアルギニンメチルトランスフェラーゼ５の選択的阻害剤
WO2020210938A1 (en) * 2019-04-15 2020-10-22 Bioardis Llc Quinazoline derivatives as cd73 inhibitors
WO2020210970A1 (en) * 2019-04-16 2020-10-22 Bioardis Llc Imidazotriazine derivatives as cd73 inhibitors
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
AU2020293263A1 (en) * 2019-06-14 2022-01-20 Southern Research Institute 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
JP7292501B2 (ja) * 2019-08-29 2023-06-16 イーライ リリー アンド カンパニー Ｃｄ７３阻害剤の結晶形態
WO2021087136A1 (en) 2019-10-30 2021-05-06 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202131932A (zh) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 作為cd73抑制劑的化合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CN119118872A (zh) 2020-03-19 2024-12-13 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
AU2021284273A1 (en) 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
WO2021257643A1 (en) * 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
CN115702150A (zh) * 2020-07-07 2023-02-14 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CN116348118A (zh) * 2020-09-08 2023-06-27 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022095975A1 (zh) * 2020-11-05 2022-05-12 武汉人福创新药物研发中心有限公司 Cd73抑制剂及其应用
CN114437038B (zh) * 2020-11-05 2025-07-25 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
CN114539340B (zh) * 2020-11-25 2024-06-07 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
WO2022109741A1 (en) * 2020-11-25 2022-06-02 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
EP4273153A4 (en) * 2020-12-29 2024-05-08 Zhejiang Vimgreen Pharmaceuticals, Ltd ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF
US20240368204A1 (en) 2021-05-11 2024-11-07 Xizang Haisco Pharmaceutical Co., Ltd. Small molecular cd73 antagonist and use thereof
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物
TW202313603A (zh) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl抑制劑化合物
WO2023061319A1 (zh) * 2021-10-11 2023-04-20 南京明德新药研发有限公司 三并环杂环衍生物
US12103943B2 (en) 2021-10-26 2024-10-01 Southern Research Institute Development of novel clofarabine analogs for cancer therapy
AU2022376961A1 (en) 2021-10-29 2024-05-16 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
JP2025516262A (ja) 2022-05-02 2025-05-27 アーカス バイオサイエンシズ インコーポレイティド 抗ｔｉｇｉｔ抗体及びその使用
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN119768155A (zh) 2022-09-14 2025-04-04 艾库斯生物科学有限公司 依曲地南的分散体
WO2024076873A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
AU2023364215A1 (en) 2022-10-20 2025-04-24 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN117924394A (zh) * 2023-09-05 2024-04-26 厦门大学 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
WO2025096979A1 (en) 2023-11-02 2025-05-08 Arcus Biosciences, Inc. Thiazole compounds as kit inhibitors and methods of use thereof
WO2025113498A1 (zh) * 2023-12-01 2025-06-05 无锡和誉生物医药科技有限公司 一种cd73抑制剂碱式盐及其制备方法和应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569650A (en) * 1993-06-11 1996-10-29 Sloan-Kettering Institute For Cancer Research C-nucleoside isosters of analogs thereof and pharmaceutical compositions
JP4118958B2 (ja) 1996-10-09 2008-07-16 ファーマセット，リミティド テトラホスホネート二環式トリス無水物
US20040266723A1 (en) * 2000-12-15 2004-12-30 Otto Michael J. Antiviral agents for treatment of Flaviviridae infections
WO2012032513A1 (en) * 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
WO2013132489A1 (en) 2012-03-05 2013-09-12 Bar-Ilan University Nucleoside 5'-phosphorothioate analogues and uses thereof
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10654884B2 (en) * 2014-04-25 2020-05-19 Boehringer Ingelheim International Gmbh Purine derivatives as CD73 inhibitors for the treatment of cancer
AU2016308717A1 (en) 2015-08-17 2018-01-25 Lupin Limited Heteroaryl derivatives as PARP inhibitors
UY37062A (es) 2016-01-08 2017-08-31 Syngenta Participations Ag Derivados de aryl oxadiazol fungicidas
AR107321A1 (es) 2016-01-08 2018-04-18 Celgene Corp Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
UA124529C2 (uk) 2016-01-08 2021-10-05 Аркус Байосайєнсіз, Інк. Модулятори екто-5-нуклеотидази та їх застосування
CN112004541A (zh) 2018-03-09 2020-11-27 艾库斯生物科学有限公司 肠道外给药的免疫增强药物
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Also Published As

Publication number Publication date
ES2963759T3 (es) 2024-04-01
JP2021167351A (ja) 2021-10-21
AU2023201288B2 (en) 2025-02-20
PL3399984T3 (pl) 2024-02-19
PT3399984T (pt) 2023-11-21
LT3399984T (lt) 2023-11-10
TW202227095A (zh) 2022-07-16
BR112018013827B1 (pt) 2024-02-20
CN114395005B (zh) 2024-12-31
JP2025123371A (ja) 2025-08-22
ZA201804350B (en) 2023-11-29
US12459967B2 (en) 2025-11-04
CN119912510A (zh) 2025-05-02
CL2018001845A1 (es) 2018-12-07
IL260260B1 (en) 2023-09-01
IL260260A (en) 2018-07-31
JP7698677B2 (ja) 2025-06-25
WO2017120508A1 (en) 2017-07-13
HRP20231155T1 (hr) 2024-01-05
US10239912B2 (en) 2019-03-26
EA201891583A1 (ru) 2019-01-31
US20240352057A1 (en) 2024-10-24
CN108697719A (zh) 2018-10-23
EP4306525A3 (en) 2024-03-20
WO2017120508A8 (en) 2018-07-05
HUE063388T2 (hu) 2024-01-28
DK3399984T3 (da) 2023-11-13
JP2023129628A (ja) 2023-09-14
US10981944B2 (en) 2021-04-20
ZA202209472B (en) 2023-06-28
TW201805006A (zh) 2018-02-16
US11001603B2 (en) 2021-05-11
US20190309010A1 (en) 2019-10-10
AU2017206061A8 (en) 2018-07-26
IL260260B2 (en) 2024-01-01
SG11201805506YA (en) 2018-07-30
CA3009196A1 (en) 2017-07-13
JP6920344B2 (ja) 2021-08-18
MX2022006322A (es) 2022-06-22
JP7322104B2 (ja) 2023-08-07
CN108697719B (zh) 2024-03-19
US20210371449A1 (en) 2021-12-02
SA518391985B1 (ar) 2022-12-19
EA038565B1 (ru) 2021-09-15
US20210002322A1 (en) 2021-01-07
UA124529C2 (uk) 2021-10-05
US20170267710A1 (en) 2017-09-21
MX2018008350A (es) 2019-05-30
EP3399984A1 (en) 2018-11-14
KR20180100638A (ko) 2018-09-11
CN114395005A (zh) 2022-04-26
EP3399984A4 (en) 2020-01-01
AU2017206061B2 (en) 2022-12-15
AU2023201288A1 (en) 2023-04-06
BR112018013827A2 (pt) 2018-12-11
US11667662B2 (en) 2023-06-06
EP3399984B1 (en) 2023-09-06
NZ744128A (en) 2024-10-25
EP4306525A2 (en) 2024-01-17
FI3399984T3 (fi) 2023-11-10
CA3009196C (en) 2022-05-31
PH12018501361A1 (en) 2019-02-27
TWI744274B (zh) 2021-11-01
CA3151595A1 (en) 2017-07-13
AU2017206061A1 (en) 2018-07-19
KR102772803B1 (ko) 2025-02-24
MY204877A (en) 2024-09-20
JP2019501223A (ja) 2019-01-17

Similar Documents

Publication Publication Date Title
SI3399984T1 (sl) Modulatorji 5'-nukleotidaze, ekto, in njihova uporaba
IL260925A (en) Dendrimer-bioadhesive polymer hydrogel nanoglue and use thereof
IL272524A (en) Clec9a binding agents and use thereof
EP4059510C0 (en) MODIFIED EXTRACELLULAR VESICLES AND THEIR USES
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL265449A (en) Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
SI3383916T1 (sl) Protitelesa proti-CD73 in njihove uporabe
SI3347379T1 (sl) ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
EP3596062A4 (en) SOMATOSTATIN MODULATORS AND THEIR USES
IL264813B (en) 2-oxo-imidazopyridines and their use
HUE060182T2 (hu) Szomatosztatin modulátorok és azok felhasználása
EP3040355A4 (en) ASPHALT MODIFYING AGENT AND ASPHALT COMPOSITION THEREWITH
EP3488832A4 (en) CONNECTION ELEMENT AND END CAPS EQUIPPED WITH A CONNECTION ELEMENT.
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
SI3290441T1 (sl) RGMA-vezavni protein in njegova uporaba
GB201621818D0 (en) Cosmetic composition and use thereof
IL256726A (en) Bisphosphonate-hbed, their radiometallic conjugates and their use as transnasal agents
SI3268374T1 (sl) KV1.3 inhibitorji in njihova medicinska uporaba
EP3665191A4 (en) SPECIFIC BRAF TCRs AND RELATED USES
SI3337506T1 (sl) Kombinacije in njihove uporabe
IL267184A (en) Phenylamidines and the use thereof as fungicides
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
EP3524640A4 (en) RESIN COMPOSITION AND MEMBRANE STRUCTURE THEREWITH
MA46235A (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
EP3573974C0 (en) RORGAMMA MODULATORS AND THEIR USES